# Genflow Biosciences links ageing science with MASH research

- Link: https://www.directorstalkinterviews.com/genflow-biosciences-links-ageing-science-with-mash-research/4121258258
- Published: 2026-08-03T09:04:00+01:00
- Author: Amilia Stone

Metabolic dysfunction-associated steatohepatitis, or MASH, is a progressive liver
disease caused by excess fat, inflammation and cellular damage in the liver. It 
was previously known as nonalcoholic steatohepatitis, or NASH, and forms part of
the broader category of metabolic dysfunction-associated steatotic liver disease.

MASH can progress from inflammation to fibrosis, cirrhosis, liver failure and liver
cancer. The disease often develops without clear symptoms, which means significant
damage may occur before diagnosis. This creates a need for earlier detection, better
disease monitoring and treatments that can address the biological processes driving
liver deterioration.

The condition is closely associated with metabolic risk factors, including obesity,
Type 2 diabetes, insulin resistance, high cholesterol, high triglycerides and high
blood pressure. However, it can also affect people who are not overweight. Its causes
and progression therefore extend beyond any single risk factor and involve a broader
breakdown in metabolic and cellular health.

Genflow Biosciences is developing gene therapies aimed at the biological mechanisms
of ageing. Its research is centred on variants of the SIRT6 gene, which is associated
with the regulation of cellular repair, metabolism, inflammation and genomic stability.

MASH’s progression involves chronic inflammation, tissue damage and fibrosis, all
of which are connected to declining cellular function.

Genflow’s SIRT6-based approach can influence the underlying processes that contribute
to liver damage. A therapy capable of improving cellular resilience, regulating 
inflammation or supporting metabolic function could have applications across several
age-related conditions. MASH provides a defined disease setting in which these mechanisms
can be studied.

_**[Genflow Biosciences plc](https://www.directorstalkinterviews.com/company/genflow-biosciences-plc/genf.l)**(
LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in
Belgium focused on developing novel therapeutic approaches that potentially halt
or slow the aging process in humans and dogs supporting longer, healthier lives_

Share on:
